CTLA4 and thyroid gland disorder: According to the largest and most extensive to date, the analysis of ir thyroid disorders based on the WHO Global Database by Bai et al., anti-PD-1/anti-PDL-1 mAbs demonstrate a higher risk of developing thyroid disorders than anti-CTLA-4 mAbs.